Search
                    Georgia Paid Clinical Trials
A listing of 1949  clinical trials  in Georgia  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1825 - 1836 of 1949
        
                Georgia is currently home to 1949 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
            
                                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    
                
                                    Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
                                
            
            
        Recruiting
                            
            
                REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP th...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/10/2024
            
            Locations: Augusta University, Augusta, Georgia         
        
        
            Conditions: Community-acquired Pneumonia, Influenza, COVID-19
        
            
        
    
                
                                    Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
                                
            
            
        Recruiting
                            
            
                Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test will be collected to test cellular response to Trikafta.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/07/2024
            
            Locations: The Emory Clinic, Atlanta, Georgia         
        
        
            Conditions: Non-cystic Fibrosis Bronchiectasis
        
            
        
    
                
                                    Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment
                                
            
            
        Recruiting
                            
            
                The purpose of this research study is to look at the advantages of using a 3D printed heart model for surgical planning in children who have been diagnosed with Congenital Heart Disease (CHD) and clinical heart failure and will undergo a ventricular assist device (VAD) placement. The investigators want to study the correlation of having a 3D printed model with improvement in patient outcomes and compare those with patients who have had a VAD placement without a 3D model.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/03/2024
            
            Locations: Children's Healthcare of Atlanta, Atlanta, Georgia         
        
        
            Conditions: Congenital Heart Disease
        
            
        
    
                
                                    Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
                                
            
            
        Recruiting
                            
            
                This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                07/02/2024
            
            Locations: Emory University School of Medicine, Atlanta, Georgia         
        
        
            Conditions: Neoplasms
        
            
        
    
                
                                    Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
                                
            
            
        Recruiting
                            
            
                This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/29/2024
            
            Locations: Phoebe Putney Memorial Hospital, Albany, Georgia         
        
        
            Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
        
            
        
    
                
                                    Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)
                                
            
            
        Recruiting
                            
            
                "To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"             
        
        
    Gender:
                ALL
            Ages:
                2 years and above
            Trial Updated:
                06/28/2024
            
            Locations: Institute of Endocrinology Diabetes, Health & Hormones, Stockbridge, Georgia         
        
        
            Conditions: Diabetes
        
            
        
    
                
                                    Virtual Reality During Exercise Testing
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to explore the effects of virtual reality use on maximal aerobic exercise test performance (aerobic capacity) in healthy adults. The main questions it aims to answer are:
* Does using a virtual reality program during a maximal aerobic exercise test lead to differences in VO2peak (maximal aerobic capacity)? and,
* Does using a virtual reality program during a maximal aerobic exercise test lead to differences in work rate at the ventilatory threshold?
Participa...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/19/2024
            
            Locations: Augusta University, Augusta, Georgia         
        
        
            Conditions: Virtual Reality
        
            
        
    
                
                                    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
                                
            
            
        Recruiting
                            
            
                The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.
Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/19/2024
            
            Locations: Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia         
        
        
            Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
        
            
        
    
                
                                    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
                                
            
            
        Recruiting
                            
            
                This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/18/2024
            
            Locations: GSK Investigational Site, Atlanta, Georgia         
        
        
            Conditions: Neoplasms
        
            
        
    
                
                                    Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
                                
            
            
        Recruiting
                            
            
                Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive triple negative breast cancer (TNBC) patients.
Assess for change in tumor-infiltrating lymphocytes (TILS) both stromal (sTILS) and intraepithelial (iTILS) in newly diagnosed early stage TNBC patients treated with two doses of MK-3475 prior to lumpectomy.             
        
        
    Gender:
                FEMALE
            Ages:
                Between 21 years and 80 years
            Trial Updated:
                06/17/2024
            
            Locations: Emory University, Atlanta, Georgia         
        
        
            Conditions: Triple Negative Breast Cancer
        
            
        
    
                
                                    Biphasic Effects of Acute Alcohol Intoxication on Bystander Intervention
                                
            
            
        Recruiting
                            
            
                The goal of this experimental study is to examine the effect of alcohol, gender, and bystander attitudes on bystander barriers and sexual violence intervention among young adult men and women (age 21-20). The main questions it aims to answer are:
* Does alcohol intoxication and gender influence bystander barriers and sexual violence intervention?
* Does alcohol intoxication have a greater impact on bystander barriers and sexual violence intervention among men, compared to women?
* Does alcohol...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 21 years and 30 years
            Trial Updated:
                06/10/2024
            
            Locations: Georgia State University, Atlanta, Georgia         
        
        
            Conditions: Alcohol Intoxication
        
            
        
    
                
                                    Natural Progesterone for the Treatment of Recurrent Glioblastoma
                                
            
            
        Recruiting
                            
            
                This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                06/09/2024
            
            Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia         
        
        
            Conditions: Gliosarcoma, Recurrent Glioblastoma
        
            
        
    